TY - JOUR
T1 - Criteria for the diagnosis of extranodal extension detected on radiological imaging in head and neck cancer
T2 - Head and Neck Cancer International Group consensus recommendations
AU - Henson, Christina
AU - Abou-Foul, Ahmad K.
AU - Yu, Eugene
AU - Glastonbury, Christine
AU - Huang, Shao Hui
AU - King, Ann D.
AU - Lydiatt, William M.
AU - McDowell, Lachlan
AU - Nagelschneider, Alex A.
AU - Nankivell, Paul C.
AU - O'Sullivan, Brian
AU - Rhys, Rhian
AU - Xiao, Youping
AU - Andrew, David
AU - Asmussen, Jon T.
AU - Bidault, Francois
AU - Dankbaar, Jan W.
AU - de Graaf, Pim
AU - Gebrim, Eloisa S.
AU - Hu, Chaosu
AU - Ding, Jianhui
AU - Kanda, Tomonori
AU - Kim, Jane
AU - Kuno, Hirofumi
AU - Medrano-Martorell, Santiago
AU - Oikonomopoulos, Nikolaos
AU - Goh, Julian Park Nam
AU - Santos-Armentia, Eloisa
AU - Schafigh, Darius G.
AU - Subramaniam, Rathan M.
AU - Wu, Xin Cynthia
AU - Yom, Sue S.
AU - Mehanna, Hisham
N1 - Publisher Copyright:
© 2024 Elsevier Ltd
PY - 2024/7
Y1 - 2024/7
N2 - Extranodal extension of tumour on histopathology is known to be a negative prognostic factor in head and neck cancer. Compelling evidence suggests that extranodal extension detected on radiological imaging is also a negative prognostic factor. Furthermore, if imaging detected extranodal extension could be identified reliably before the start of treatment, it could be used to guide treatment selection, as patients might be better managed with non-surgical approaches to avoid the toxicity and cost of trimodality therapy (surgery, chemotherapy, and radiotherapy together). There are many aspects of imaging detected extranodal extension that remain unresolved or are without consensus, such as the criteria to best diagnose them and the associated terminology. The Head and Neck Cancer International Group conducted a five-round modified Delphi process with a group of 18 international radiology experts, representing 14 national clinical research groups. We generated consensus recommendations on the terminology and diagnostic criteria for imaging detected extranodal extension to harmonise clinical practice and research. These recommendations have been endorsed by 19 national and international organisations, representing 34 countries. We propose a new classification system to aid diagnosis, which was supported by most of the participating experts over existing systems, and which will require validation in the future. Additionally, we have created an online educational resource for grading imaging detected extranodal extensions.
AB - Extranodal extension of tumour on histopathology is known to be a negative prognostic factor in head and neck cancer. Compelling evidence suggests that extranodal extension detected on radiological imaging is also a negative prognostic factor. Furthermore, if imaging detected extranodal extension could be identified reliably before the start of treatment, it could be used to guide treatment selection, as patients might be better managed with non-surgical approaches to avoid the toxicity and cost of trimodality therapy (surgery, chemotherapy, and radiotherapy together). There are many aspects of imaging detected extranodal extension that remain unresolved or are without consensus, such as the criteria to best diagnose them and the associated terminology. The Head and Neck Cancer International Group conducted a five-round modified Delphi process with a group of 18 international radiology experts, representing 14 national clinical research groups. We generated consensus recommendations on the terminology and diagnostic criteria for imaging detected extranodal extension to harmonise clinical practice and research. These recommendations have been endorsed by 19 national and international organisations, representing 34 countries. We propose a new classification system to aid diagnosis, which was supported by most of the participating experts over existing systems, and which will require validation in the future. Additionally, we have created an online educational resource for grading imaging detected extranodal extensions.
UR - http://www.scopus.com/inward/record.url?scp=85196632609&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(24)00066-4
DO - 10.1016/S1470-2045(24)00066-4
M3 - Review article
C2 - 38936388
AN - SCOPUS:85196632609
SN - 1470-2045
VL - 25
SP - e297-e307
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 7
ER -